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Abstract: Angiogenesis has long been recognized as an essential element in tumor growth. 
Since the conception of antiangiogenesis for cancer therapeutics, great strides have been 
made in understanding the molecular biology underlying angiogenesis, both in cancer and in 
physiology. By capitalizing on these advancements through bench-to-bedside research, potent 
antiangiogenic agents have been developed and tested. To date, the clinical results of most of 
these antiangiogenic agents have not met expectations. Even with the most successful agents, 
such as bevacizumab, used either as single agents or in combination with chemotherapy, gains 
in overall survival of cancer patients have been modest in most cases. In this article, the authors 
present the evolving views of antiangiogenic therapy, review recent experimental and clinical 
studies on antiangiogenesis, and address the fundamental role of hypoxia in tumor progression, 
which may be key to improving the efficacy of antiangiogenic therapy.
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Angiogenesis, tumor growth, and antiangiogenesis
Recognition of the association between vigorous neovascularization (angiogenesis) 
and tumor growth dates back to the first half of the 20th century.1,2 However, the sig-
nificance of this finding and the relationship between new vessel growth and tumor 
growth were not fully appreciated until many years later. Folkman and others first 
showed that, in the absence of vascularization, tumor growth arrested when the tumor 
reached 2–3 mm in diameter, presumably owing to limited diffusion of oxygen, nutri-
ents, and waste products. Furthermore, small, dormant tumors would quickly resume 
expansion when allowed to initiate neovascularization.3–5
An angiogenic factor was later isolated from human and animal tumors that is 
mitogenic to endothelial cells and stimulates the rapid formation of new capillaries in 
animals.6 Folkman proposed targeting this angiogenic factor for angiogenic inhibition 
as a strategy for cancer therapy, which is the fundamental premise of antiangiogenesis 
therapy. This unconventional approach seemed promising for several reasons. First, 
fewer side effects were expected from inhibiting angiogenesis than from traditional 
cytotoxic agents, presumably because new vessel growth in an adult patient is less 
important under most physiologic conditions (eg, in the absence of wound heal-
ing). Second, it seemed plausible that, in addition to restricting tumor growth to the 
limits of direct diffusion of nutrients and waste metabolites, reduced access to the 
vasculature would decrease distant metastasis. Third, by targeting the vasculature, 
one would expect less likelihood of developing resistance from endothelial cells than 
from tumor cells.7,8Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Identifying this angiogenic factor, however, proved 
to be challenging. In time, it became apparent that there 
were many different factors involved in stimulating angio-
genesis. The first to be identified was the basic fibroblast 
growth factor (bFGF),9 which was shown to directly 
stimulate endothelial cell proliferation.10 A few years later, 
vascular endothelial growth factor (VEGF) was identi-
fied, cloned,11,12 and characterized as a potent regulator of 
angiogenesis via mitogenic and antiapoptotic signaling in 
endothelial cells.13,14 As an increasing number of angiogenic 
regulators were identified and characterized, including 
the angiopoietins,15,16 interleukin 8,17,18 and others, a more 
cohesive view of the mechanisms of angiogenesis in tumor 
growth developed.
Angiogenic switch
In 1991, Hanahan and colleagues further developed the 
theory that angiogenesis is required for continued tumor 
growth by demonstrating a switch from low to high vessel 
density during the multistep process of fibrosarcoma progres-
sion in transgenic mice.19 It was found that cells cultured 
from advanced preneoplastic lesions secreted bFGF into the 
growth medium, whereas cells derived from lower-grade 
lesions did not. This ‘angiogenic switch’ correlated not 
only with histologically higher-grade tumors but also with 
tumorigenicity. Similar results seen in islet cell carcinoma 
and epidermal squamous cell carcinoma mouse models added 
additional evidence to the idea that the switch to an angio-
genic phenotype is a discrete step during tumor progression 
and essential for solid tumor growth.20
The importance of tumor angiogenesis became more 
apparent as the underlying mechanisms began to come 
into focus. Folkman’s vision of developing antiangiogenic 
cancer therapies also began to seem within reach as interest 
increased. This step forward, however, did not come without 
hindrance.
Setbacks for antiangiogenic therapy
Despite the promising preclinical and animal model data, 
almost none of the early agents identified and tested have 
made it past clinical trials. A new use for thalidomide, 
which was originally introduced as a sedative and antiemetic 
drug, was postulated after its metabolites were found to 
inhibit angiogenesis in a rabbit cornea micropocket assay.21 
  Unfortunately, early trials showed only modest clinical 
effectiveness in prostate cancer patients and no antitumor 
activity in recurrent or metastatic squamous cell carcinoma 
of the head and neck.22,23
Trials of a host of other antiangiogenic drugs followed 
with similar results. TNP-470, an analog of fumigillin, gener-
ated only one short-lived partial response in 33 patients with 
metastatic renal carcinoma,24 and a later study also failed to 
show clinical benefit for prostate cancer.25 In two phase I clini-
cal trials, angiostatin, which is a naturally occurring angio-
genesis inhibitor,26 showed no clinical response with several 
types of solid tumors.27,28 Likewise, endostatin, another 
natural angiogenesis inhibitor,29 showed only minor antitumor 
activity in a phase I trial30 and no significant tumor regres-
sion in patients with advanced neuroendocrine tumors in a 
phase II trial.31 In a phase II clinical trial of ABT-510, which 
is a peptide mimetic of thrombospondin type 1 (yet another 
endogenous angiogenesis inhibitor), only 3 out of 21 late-
stage malignant melanoma patients showed stable disease, 
and no definite clinical efficacy was demonstrated.32 Another 
phase II trial also showed only one objective response out of 
88 patients with advanced soft tissue sarcoma.33
The mechanisms of action for all the previously dis-
cussed drugs are poorly or only partially understood. Agents 
with specific molecular targets in the angiogenic signaling 
pathways were explored as alternatives. This approach, 
however, also had several disappointments before any 
measure of clinical success was achieved. SU5416, which 
is a small synthetic receptor tyrosine kinase inhibitor of the 
VEGF receptor VEGFR-2, produced no objective response 
in 27 patients with refractory multiple myeloma. Two other 
phase II trials showed either no or rare responses in patients 
with advanced soft tissue sarcomas and recurrent head and 
neck cancers.34 PTK787/ZK 222584, which is another small 
molecule tyrosine kinase receptor inhibitor targeting all of the 
VEGF receptors, also failed to produce significant responses 
in patients with acute myeloid leukemia.35
Signs of success
In 2003, an anti-VEGF humanized monoclonal antibody, 
bevacizumab, made its debut with only slightly better results 
as a monotherapy in metastatic renal cancer patients;36 when 
compared with a placebo, high-dose bevacizumab had only 
a 10% response rate with modestly prolonged progression-
free survival but no overall survival benefit. Although these 
initial results were disappointing, evidence of the efficacy of 
bevacizumab came shortly thereafter, leading to an eventual 
paradigm shift in the concept of antiangiogenic therapy. 
In June 2004, Hurwitz et al reported a phase III trial showing 
substantial improvement in overall survival (about a 5-month 
increase) in patients with metastatic   colorectal cancer 
when treated with bevacizumab combined with   irinotecan, Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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fluorouracil, and leucovorin.37 Although a handful of phase III 
trials involving treatment of different cancers by combining 
bevacizumab with various regimens have shown improvement 
only in progression-free survival but not overall survival,38–40 
most reported studies have shown increased overall survival 
along with increased progression-free survival when beva-
cizumab is added to the treatment regimen. These include a 
2-month overall survival benefit in patients with metastatic 
renal cell carcinoma when treated with bevacizumab in 
combination with interferon α-2a;41 in patients who had 
previously been treated for metastatic colorectal cancer when 
combined with oxaliplatin, fluorouracil, and leucovorin;42 and 
in patients with non-small-cell lung cancer when combined 
with paclitaxel and carboplatin.43 A 3-month overall survival 
benefit was also reported in patients with metastatic colorec-
tal cancer treated with bevacizumab in combination with 
fluorouracil and leucovorin.44 Therefore, in most cases, an 
apparent synergy is seen in which bevacizumab has clinical 
benefit when combined with cytotoxic chemotherapies.
It is also interesting to note that thalidomide, as discussed 
earlier, has not been proven effective as a monotherapy, 
but, when combined with melphalan, a cytotoxic alkylating 
agent, and prednisone, an immunosuppressing corticosteroid, 
it increases median overall survival by nearly 18 months 
in elderly patients with multiple myeloma,45 possibly by 
  reducing bone marrow vascularization.46 Still, even with these 
first signs of success involving bevacizumab and thalidomide, 
tumors did become resistant relatively quickly and overall 
improvement was modest.
Normalization of tumor vasculature
With these clinical data has come a paradox. If antiangio-
genic therapy destroys tumor vasculature, a reduction of drug 
delivery would be expected. Why then does antiangiogen-
esis enhance tumor killing when combined with cytotoxic 
agents? Perhaps even more puzzling is the observation that 
anti-VEGF therapy can increase tumor irradiation efficacy,47 
which is largely dependent on tissue oxygenation.
To account for these apparently conflicting findings, 
Jain posited that, in addition to destroying vasculature for 
depriving the tumor of oxygen and nutrients, antiangiogenic 
agents also transiently ‘normalize’ the abnormal structure 
and function of tumor vasculature to make it more efficient 
for oxygen and drug delivery.48 Vasculature maintenance 
involves a homeostatic interplay between pro- and antiangio-
genic signals. In normal tissue these signals are balanced, but 
during neoplastic growth the proangiogenic signals are over-
expressed, thereby stimulating inappropriate   vessel growth 
and leading to characteristically disorganized,   inefficient, 
and leaky tumor vasculature. Jain proposed that using a low 
dose or ‘judicious’ application of antiangiogenic agents 
could restore the balance in the angiogenic regulation by 
pruning immature, nonproductive vessels, decreasing vessel 
permeability, and reducing abnormal dilation. The expected 
functional consequence of vasculature normalization is 
decreased interstitial fluid pressure, relieved hypoxic stress, 
and improved penetration of drugs in the tumor.
Although vasculature normalization has been shown to 
improve vascular function in preclinical models through intra-
vital imaging studies,49 it is not straightforward to ascertain 
in patients the changes in blood flow and distribution within 
a tumor during antiangiogenic therapy, making it difficult 
to verify this process. Many questions, such as why there is 
only a transient ‘normalization window’ and how to identify 
it, remain unanswered.
Negative sequelae of targeting  
tumor vasculature
As mentioned earlier, a potential advantage of targeting 
endothelial rather than tumor cells is the avoidance of drug 
resistance, because endothelial cells, unlike those of tumors, 
are genetically stable.7 However, tumor revascularization 
following a transient decrease in vessel density with an anti-
VEGF receptor agent has been reported, resulting at least in 
part from increased levels of bFGF.50
It has become increasingly clear that VEGF-targeted 
therapy probably involves multiple mechanisms.51 A pos-
sible explanation for the activation of alternative angio-
genic pathways, however, is that antiangiogenesis induces 
hypoxia, resulting in activation of the hypoxia-inducible 
factor α (HIF-α), which in turn triggers revasculariza-
tion of the tumor. HIF-α is known to transcriptionally 
upregulate a host of pro- and antiangiogenic genes encod-
ing placental growth factor, angiopoietin 1, angiopoietin 
2, stromal-derived factor 1, platelet-derived growth factor, 
and bFGF, as well as VEGF.52 Given that overexpression 
of HIF-1α, one of the HIF-α family members (see below), 
induces nonleaky hypervascularity in transgenic mice,53 
it is conceivable that activated HIF-α could upregulate 
both pro- and antiangiogenic factors for neovasculariza-
tion in tumors. Indeed, mice haplodeficient in Egln1, 
which encodes a negative regulator of HIF-α (see below), 
showed normalized endothelial lining and vessel matura-
tion, thereby resulting in improved tumor oxygenation with 
decreased tumor invasiveness, even though tumor growth 
was not inhibited.54Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Irrespective of vasculature regression and/or normalization, 
a more serious concern with antiangiogenic therapy is that 
vessel regression may drive tumors toward a more locally 
invasive and distantly metastatic phenotype. Indeed, 
increased invasiveness in glioblastoma models was observed 
after systemic antiangiogenic therapy with an antibody 
against VEGFR-2, despite a marked inhibition of tumor 
growth and microvessel density.55,56 Similar results were seen 
after treatment with bevacizumab in another glioblastoma 
preclinical study.57 In addition, increased invasiveness after 
anti-VEGFR-2 treatment was also seen in a pancreatic neuro-
endocrine cancer mouse model, along with increased liver and 
lymph node metastases.58 Furthermore, short-term   treatment 
with a potent angiogenic inhibitor, sunitinib/SU11248, also 
accelerated metastasis into multiple organs in a preclini-
cal study using breast cancer and melanoma cells.59 More 
troubling is that the invasive nature of the tumors seemed 
to be permanently established, as removal of treatment did 
not relieve the aggressive phenotype, possibly suggesting a 
genetic transformation. Although this increased invasiveness 
in response to antiangiogenic therapy has not been unequivo-
cally confirmed in patients, partially because of imaging 
limitations in evaluating these tumors (ie, FLAIR magnetic 
resonance imaging), it has nonetheless been observed at least 
subjectively.60 A review of literature indicates that although 
glioblastoma patients benefit greatly from reduced cerebral 
edema and intracranial pressure through angiogenic inhibi-
tion, tumor invasion continues.61 Additional concerns include 
that the normalization of tumor vasculature by antiangiogenic 
agents may restore the blood–brain barrier function, thereby 
antagonizing the efficacy of chemotherapeutic drugs.
HiF-1α, genetic alteration,  
and tumor progression
Hypoxia has long been implicated in genetic instability and 
tumor progression, which may account for the inevitable 
failure of antiangiogenesis as a monotherapy. Although the 
mechanisms underlying hypoxia-induced tumor progression 
remain to be elucidated, recent evidence indicates that HIF-α 
plays an essential role in tumor growth and progression.
In human cancers, both HIF-1α and HIF-2α, two of 
the prevalent members of the HIF-α family, are frequently 
dysregulated, resulting in their overexpression.62 Under 
physiological conditions when oxygen tension within cells 
is high, HIF-α is hydroxylated at specific proline residues 
by the prolyl hydroxylases EGLN1, EGLN2, and EGLN3 
(better known as PHD2, PHD1, and PHD3, respectively).63,64 
This allows HIF-α to be ubiquitinated by a pVHL-directed 
E3 ligase and targeted to the proteasome for degradation. In 
hypoxia, however, the hydroxylation reaction is   inhibited; 
HIF-α accumulates within the cell, translocates to the 
nucleus, and, upon dimerization with its binding partner aryl 
hydrocarbon receptor nuclear translocator (ARNT), acts as 
a transcription factor for the activation of a diverse group of 
hypoxia-responsive genes.52 This canonical HIF-α–ARNT 
pathway (Figure 1) has accounted for hypoxic activation of 
many genes directly related to tumor growth and survival, 
such as those involved in glycolysis, cell migration, apopto-
sis, multidrug resistance, extracellular matrix modification, 
epithelial–mesenchymal transition, and angiogenesis.62,65
Despite these extraordinary insights into the mechanisms 
underlying tumor biology, how hypoxia drives genetic altera-
tion, the underlying cause of tumor progression, has yet to 
be elucidated.66,67 Interestingly, we and others began to show 
recently that HIF-1α and HIF-2α have opposing effects on 
DNA repair; HIF-1α inhibits, whereas HIF-2α stimulates, 
DNA repair.68,69 Although how these conflicting effects 
between HIF-1α and HIF-2α are reconciled within tumor 
cells needs further investigation, our results demonstrated that 
HIF-1α, but not HIF-2α, is essential to hypoxic downregula-
tion of the DNA mismatch repair genes MSH2 and MSH6  70 
and the double-strand break repair gene NBN.71 Interestingly, 
HIF-1α does so by a distinct mechanism that is independent 
of the HIF-1α–ARNT pathway but involves HIF-1α func-
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Figure  1  A  schematic  representation  of  the  HiF-1α–ARNT  pathway  and  the 
HiF-1α–c-Myc  pathway.  Stabilized  HiF-1α  participates  in  the  canonical  HiF-1α–
ARNT pathway (–ARNT) through dimerization with its binding partner ARNT, 
recruitment of the transcription coactivator p300/CBP, and binding to the HRe in 
the promoter of the angiogenic and glycolytic genes for transcriptional activation. 
Alternatively, the HiF-1α–c-Myc pathway (–c-Myc) involves HiF-1α competing with 
c-Myc for binding to the transcription factor Sp1 in the promoter of DNA repair 
genes, resulting in selective c-Myc displacement and gene repression.
Abbreviations: HiF, hypoxia-inducible factor; ARNT, aryl hydrocarbon receptor 
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tionally counteracting c-Myc, a transcriptional activator for 
maintaining DNA repair gene expression. This HIF-1α–c-
Myc pathway72 accounts not only for hypoxic inhibition of 
DNA repair but also for resultant DNA damage and genetic 
alterations (Figure 1). By uncoupling these two distinct, 
independent pathways of HIF-1α, we have recently shown 
that the HIF-1α–c-Myc pathway is essential to drive tumor 
progression, whereas the HIF-1α–ARNT pathway is more 
involved in tumor growth.73 Therefore, the dual functions of 
HIF-1α may account on the one hand for vasculature normal-
ization resulting from regulated expression of both pro- and 
antiangiogenic genes via the HIF-1α–ARNT pathway, and 
on the other hand for tumor progression driven by genetic 
alterations via the HIF-1α–c-Myc pathway.
With this gained knowledge, we propose that in addition 
to its important role in angiogenesis and glycolysis for tumor 
growth and survival, HIF-1α is essential to drive genetic 
alteration for tumor progression, which is a negative aspect 
of the hypoxic response74 enabling tumor cells to evolve 
through increased genetic heterogeneity. This could explain 
the ease with which many cancers are able to adapt to a 
wide variety of therapeutics (including antiangiogenics) and 
develop resistance. It could also explain the apparent genetic 
changes that lead to increased invasion and metastasis in 
antiangiogenic-treated tumors.
Future directions  
of antiangiogenic therapy
Although antiangiogenic therapy remains promising,51 a 
durable antitumor activity for an improved overall survival is 
desired. To this end, several hypotheses have been   proposed. 
Pietras and Hanahan suggested the use of broader-spectrum 
  angiogenesis inhibitors or ‘cocktails’ of specific inhibitors 
as a method of blocking alternative angiogenic pathways 
that may be activated under a VEGF blockade.75 They have 
demonstrated the efficacy of this tactic in an animal model 
of islet cell carcinogenesis. Treatment with anti-VEGFR-2 
antibodies led to an initial decrease in tumor vascularity as 
well as tumor size. This was followed by revascularization and 
regrowth of the tumors. Greater response was seen, however, 
by coinhibiting bFGF, which was suspected in an alternative 
angiogenic pathway. This resulted in a further decrease in 
tumor growth after the initial regression.
On the other hand, it stands to reason that if HIF-α can 
be targeted alongside antiangiogenic agents to prevent the 
induction of genetic alteration and/or angiogenesis, this 
could greatly improve the efficacy of antiangiogenic therapy. 
Interestingly, Melillo and Rapisarda et al have identified a 
potential HIF-α inhibitor, topotecan.76,77 When used alongside 
bevacizumab in U251 glioma xenografts, topotecan showed 
considerable synergistic antitumor activity. Not only was 
tumor volume decreased but intratumor vasculature was 
also decreased compared with tumors treated with either 
topotecan or bevacizumab alone.78 Considering the increased 
invasive nature of tumors following antiangiogenic treat-
ment, HIF-α targeting may prove to be an effective way of 
maximizing antiangiogenic therapy in the future. Likewise, 
drugs that potentially block genetic alteration and thereby 
tumor progression may greatly improve overall survival when 
combined with   antiangiogenic agents.
Conclusions
Antiangiogenic therapy was initially based on the notion 
that angiogenesis is required for tumor growth, and thus 
Vessel
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Figure 2 A hypothetic model illustrates that malignant progression results from antiangiogenic therapy. Angiogenic inhibition deprives tumor cells of oxygen and nutrients, 
resulting in vessel regression and thereby death of the majority of the tumor cells. However, hypoxic cells harbored within the solid tumor are able to tolerate severe 
hypoxia by undergoing genetic alterations for malignant progression via the HiF-1α–c-Myc pathway and by inducing angiogenesis and glycolysis for cell proliferation via the 
HiF-1α–ARNT pathway.
Abbreviations: HiF, hypoxia-inducible factor; ARNT, aryl hydrocarbon receptor nuclear translocator.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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  destruction of the tumor vasculature would deprive the 
tumor of oxygen and nutrients, resulting in growth inhibi-
tion. However, tumor vasculature is structurally abnormal 
and functionally inefficient, and the resultant hypoxic 
microenvironment is associated with tumor progression 
and resistance to therapies (Figure 2). Therefore, thera-
peutic destruction of the tumor vasculature is expected to 
yield more severe hypoxia, which on the one hand induces 
additional angiogenic responses through the activation of 
HIF-α for normalizing vasculature, and on the other hand 
drives genetic alteration for malignant progression. This view 
accounts for the unexpected clinical outcomes when single 
antiangiogenesis agents are used, some clinical benefits 
when antiangiogenesis agents are used in combination with 
chemotherapy, and fundamentally the inevitable problem of 
angiogenic therapy, which is that hypoxia promotes tumor 
progression. Thus, targeting tumor hypoxia may improve the 
efficacy of angiogenic therapy.
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